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AbstrAct
Stromal cells like synovial fibroblasts gained great interest 
over the years, since it has become clear that they strongly 
influence their environment and neighbouring cells. The 
current review describes the role of synovial fibroblasts as 
cells of the innate immune system and expands on their 
involvement in inflammation and cartilage destruction in 
rheumatoid arthritis (RA). Furthermore, epigenetic changes 
in RA synovial fibroblasts and studies that focused on the 
identification of different subsets of synovial fibroblasts are 
discussed.
In most autoimmune diseases, including 
rheumatic diseases, research focused on the 
analysis of immune cells and their role in 
initiation and perpetuation of disease. Since a 
couple of years, however, it has been acknowl-
edged that immune cells and local stroma 
have a significant role in disease pathogen-
esis. Stromal cells reveal an unexpected 
complexity in phenotype and function in 
different organs and in different diseases.
The stroma builds the structural framework 
of an organ or tissue. Studies analysing stromal 
cells in different settings revealed interac-
tions between stromal cells and immune cells, 
which substantially contribute to shaping the 
immune response. Furthermore, stromal cells 
were recognised to have immunological func-
tions and to be able to recognise pathogens 
and elicit an immune response. Intestinal, 
dermal, gingival and synovial fibroblasts are 
only some examples of stromal cells that have 
been shown to express innate immune recep-
tors, in particular toll-like receptors (TLR). 
They react with the production of cytokines 
and chemokines to pathogen sensing and are 
able to process and to present antigens via 
major histocompatibility complex (MHC) II 
receptors.1–5 Therefore, these cells are part 
of the innate immune system and play an 
important role as local pathogen and damage 
sensors and activators of the immune system.
Synovial fibroblasts are the main stromal 
cells of the joint synovium. They are found in 
the synovial sublining and lining layer, which, 
in a healthy joint, is one to two cell layers 
thick and is interspersed with tissue-resident 
macrophages. Synovial fibroblasts produce 
the extracellular matrix (ECM) components 
of the synovial fluid and thus are important 
for cartilage integrity and lubrication of the 
joint. In rheumatoid arthritis (RA), the lining 
layer thickens and immune cells infiltrate the 
sublining layer of the synovium (figure 1). 
Synovial fibroblasts proliferate, become acti-
vated and invade and destroy the adjacent 
cartilage.
The analysis of synovial fibroblast in RA 
reaches back to the late 60s and early 70s with 
first studies done in particular by HG Fass-
bender and CW Castor and colleagues. Already 
in 1972, Castor and Buckingham noted that 
‘extracts of Gram-negative bacteria, applied 
to fibroblast cultures, markedly increased 
hyaluronic acid production, glucose utilisa-
tion, and lactate output’,6 anticipating studies 
on TLR signalling and metabolic changes 
in synovial fibroblasts that were published 
decades later. Since then, numerous studies 
have characterised many different aspects of 
synovial fibroblast biology. Usually, cultured 
synovial fibroblasts from patients undergoing 
joint replacement surgery or synovial biop-
sies were used for these studies. Thereby, 
the synovium is enzymatically digested or 
fragmented, and adherent cells are used for 
analysis after three to four passages.7 These 
cultures are highly homogeneous for the 
expression of fibroblasts markers such as 
CD90 or proly-4-hydroxylase. However, it 
should be kept in mind that long-term culture 
of synovial fibroblasts can have an influence 
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Key messages
 ► Synovial fibroblasts are carry a variety of innate 
immune receptors and are able to present antigen.
 ► in rheumatoid arthritis (RA), synovial fibroblasts 
promote joint destruction via their attachment to 
cartilage and thus are key cells in RA pathogenesis.
 ► RA synovial fibroblasts are stably activated and 
show alterations in their epigenetic landscape.
 ► Synovial fibroblasts of different joints and of the 
lining and sublining layer differ in their phenotype 
and thus represent distinct subtypes of the synovial 
fibroblast population.
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Figure 1 Osteoarthritis (A) and rheumatoid arthritis (RA) 
synovium (B). Synovial fibroblasts are found in the lining as 
well as in the sublining layer of the synovium. Thickening 
of the lining layer, lymphocytic infiltration and increased 
formation of blood vessels can be seen in RA synovium.
on their phenotype and that some characteristics of syno-
vial fibroblasts, for example, the proliferative potential 
change over several passages.8 9 Furthermore, it has not 
yet been clarified how homogeneous this cultured cell 
population is, considering that different subtypes of 
synovial fibroblasts have been described as mentioned in 
more detail below.
Due to the vast amount of studies conducted with 
synovial fibroblasts in various rheumatic diseases, not 
all aspects of synovial fibroblast function in health and 
disease can be covered by the current review article. 
Instead, it focuses on the role of synovial fibroblasts 
as innate immune cells, their interaction with other 
immune cells and how this influences the pathogenesis of 
RA. Furthermore, epigenetic changes and their potential 
consequences in RA synovial fibroblasts are mentioned, 
and studies that subcategorise synovial fibroblasts into 
different subsets based on functional and embryonic 
differences are discussed.
Synovial fibroblaSTS aS innaTe immune CellS
By the expression of various pattern recognition recep-
tors, synovial fibroblasts are well equipped to sense 
invading pathogens as well as joint damage. Synovial 
fibroblasts express TLR1–7, but very low or not-detect-
able basal transcript levels of TLR8–10.2 10
TLR3 and TLR7 bind double-stranded and single-
stranded RNA, respectively. In addition, the cytosolic 
pattern recognition receptors (PRR) RIG-I and MDA5, 
which both bind double-stranded RNA are expressed and 
active in synovial fibroblasts.10 Necrotic cells in the syno-
vial fluid were suggested to be a possible source of endog-
enous ligands leading to the activation of TLR3-mediated 
pathways in synovial fibroblasts in RA.11 In a large scale 
comparison of cytokine profiles between RA synovial 
fluid and stimulated synovial fibroblasts, the cytokine 
profiles obtained by stimulation of synovial fibroblasts 
with tumour necrosis factor (TNF) α, interleukin (IL) 1 
or the TLR3 ligand Poly(I:C) reached the highest simi-
larity with RA synovial fluids among 10 different stimuli 
used.12 The seven cytokines most strongly induced by 
these stimuli in synovial fibroblasts were also among the 
12 cytokines with the highest levels in RA synovial fluids, 
corroborating the strong contribution of synovial fibro-
blasts to the inflammatory environment in RA joints. 
Unfortunately, other TLR ligands were not included in 
the stimulation experiments in this study.
TLR2, which forms heterodimers with TLR1 or TLR6, 
and TLR4 are both sensors of bacterial lipoproteins. A 
variety of endogenous ligands have been described to 
bind and activate TLR2 and TLR4, and many of them have 
been found at increased levels in RA joints.13–17 Some like 
heat-shock proteins, low-molecular-weight hyaluronan or 
high-mobility group protein 1 were initially described as 
direct ligands, but highly purified preparations were later 
not confirmed to stimulate TLR activation.18–20 Instead, 
it was suggested that these molecules facilitate binding 
of TLR ligands and thus amplify the cellular response to 
TLR activation. However, it is not clear in how far recom-
binant or highly purified preparations resemble their 
counterparts in vivo. Post-translational modifications 
and the formation of immune complexes can influence 
binding and activity of TLR ligands in vivo. Fibrinogen, 
which was described as endogenous ligand of TLR4,21 
was shown to be more potent to activate macrophages 
and synovial fibroblasts in its citrullinated form.22 23 Also 
free histones that can activate TLR2 and TLR424 were 
found to be more potent stimulators if citrullinated and 
even more if incorporated in an immune complex.25 
Interestingly, activation of monocytes by synovial fluids 
was significantly better blocked with an anti-TLR4 anti-
body if the patients had anti-citrullinated protein anti-
bodies (ACPA) directed against citrullinated fibrinogen 
and citrullinated histone 2A, pointing toward a strong 
contribution of TLR4-mediated disease pathways in 
these patients.26 Thus, in the RA joint environment, the 
high levels of protein citrullination and the formation 
of immune complexes comprising citrullinated proteins 
and ACPA might further promote the binding of endog-
enous ligands to TLRs and cellular activation.
Interestingly, high content of citrullinated peptides 
was found in exosome preparations from synovial fluids 
of patients with RA, osteoarthritis (OA) and reactive 
arthritis, suggesting that extracellular vesicles might be 
of importance in the distribution and presentation of 
citrullinated peptides to various cell populations.27 Even 
though the amount of exosomes was similar between the 
patient’s groups, the content of proteins differed in that 
α2-macroglobulin, IgG1 γ-chain and fibronectin were 
only present in RA exosomes.27 Plasma-derived extra-
cellular vesicles from RA patients but not from healthy 
individuals were shown to activate TLR4 on human 
embryonic kidney cells, on human monocytic cell lines 
and on murine bone-marrow derived monocytes.28 The 
authors could show that oxidised lipids in the membrane 
of RA exosomes were responsible for the activation of 
TLR4 and that the subsequent response resulted in the 
upregulation of genes that are important in resolving 
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rather than promoting inflammation and substantially 
differed from a  lipopolysaccharide-induced response. 
Synovial fibroblasts were found to produce proinflam-
matory mediators on incubation with extracellular vesi-
cles.29–31 Even though it remains to be analysed whether 
extracellular vesicles from RA synovial fluid can elicit 
a specific TLR4 response in synovial fibroblasts, these 
studies support the hypothesis that extracellular vesicles 
with RA-specific content and/or modifications might 
activate synovial fibroblasts via TLR4 and thus modulate 
inflammation and joint destruction.
There are not many published studies investigating the 
expression and function of TLR9 and other DNA sensors 
such as AIM2 in synovial fibroblasts, and thus, it is not yet 
clarified in how much synovial fibroblasts can contribute 
to an immunoresponse induced by DNA sensing.32 After 
24-hour stimulation with unmethylated CpG-rich DNA, 
the ligand of TLR9, no increase in protein levels of IL 6 
or IL-8 could be measured,33 and only a small increase 
in transcript levels of IL-6 and IL-8 was measured after 
4 hours of stimulation.34 An interesting study published 
in 2017 could show that neutrophil extracellular traps 
(NETs) can be internalised by synovial fibroblasts via a 
pathway involving the receptor for advanced glycation 
end-products and TLR9.35 Internalisation of NETs led to 
upregulation of MHC class II by synovial fibroblasts via 
IL-17B and presentation of citrullinated peptides to anti-
gen-specific T cells. Injection of synovial fibroblasts that 
had internalised NETs into humanised HLA-DRB*04:01 
transgenic mice led to formation of auto-antibodies 
against citrullinated histones H3 and H4 and citrulli-
nated myeloperoxidase, which are all constituents of 
NETs,35 proving the effectiveness of antigen presentation 
by synovial fibroblasts. Earlier studies also showed that 
synovial fibroblasts in vivo and in vitro,9 mainly after stim-
ulation with interferon γ (IFNγ),36 37 express MHC class 
II and that they can present antigens to T cells.38 It would 
be interesting to see whether also TLR stimulation can 
influence the expression and function of MHC class II in 
synovial fibroblasts as it was described in other cell types.
Once activated, TLRs were shown to induce the produc-
tion of cytokines, chemokines and matrix metalloprotein-
ases (MMPs) in synovial fibroblasts.2 12 39 High levels of 
the B cell survival factors B cell activating factor (BAFF) 
and a proliferation-inducing ligand (APRIL) produced 
by synovial fibroblasts after TLR3 stimulation promote 
antibody production and class switching of B cells.40 
Interestingly, stimulation of one PRR also influences the 
expression of others. Stimulation of TLR3 in synovial 
fibroblasts leads to a robust upregulation of TLR3 itself, 
TLR2 and the cytoplasmic PRRs NOD1 and NOD2, which 
both sense bacterial products.2 41 42 Activation of NOD1 
in turn synergises with TLR2 and TLR4 pathways.42 
Therefore, activation of one PRR increases the reactivity 
of synovial fibroblasts to various endogenous and exog-
enous PRR ligands, which in an environment with high 
levels of endogenous ligands such as the RA synovium 
might lead to a constant build-up of the proinflammatory 
response. Furthermore, in contrast to macrophages, the 
production of proinflammatory cytokines is not damp-
ened after repeated stimulation of TLRs in synovial fibro-
blasts.43 This lack of tolerisation might further contribute 
to sustaining the inflammatory response in RA synovium.
For the sake of completeness, it should be mentioned 
that several other stimuli, for example, a variety of cyto-
kines, growth factors44 and adipokines,45–47 were found 
to activate synovial fibroblasts and promote their proin-
flammatory and joint destructive behaviour. However, it 
would go beyond the scope of this review to discuss all of 
them.
inTeraCTionS of Synovial fibroblaSTS wiTh T CellS
Based on findings that various types of stromal cells such 
as bone marrow-derived mesenchymal stem cells and 
dermal and synovial fibroblasts inhibit T cell prolifera-
tion, it has been proposed that stromal cells in general 
possess immunosuppressive properties.48 49 For the 
suppression of T cell proliferation by synovial fibroblasts, 
soluble factors are needed that are only induced in syno-
vial fibroblasts via direct cell-cell contact between synovial 
fibroblasts and T cells.49 50 A recent study could show that 
the inhibition of T cell proliferation is at least partly medi-
ated via depletion of tryptophan by synovial fibroblasts.50 
This study also showed that OA synovial fibroblasts are 
more efficient in suppressing T cell proliferation than RA 
synovial fibroblasts.
Whereas some studies showed that co-culture of T 
cells with synovial fibroblast reduced the production of 
IFNγ and IL-10, but not tumour necrosis factor (TNF) 
or IL-17A by T cells,49 50 other studies showed increased 
production of IFNγ, TNF and IL-17 by T cells co-cultured 
with synovial fibroblasts.51 52 This effect was mediated via 
membrane-bound IL-1551 and the CD40 pathway.52 The 
discrepancies between these studies probably stem from 
differences in isolation, culturing and stimulation tech-
niques. It is hard to estimate which in vitro system most 
closely reflects the situation in vivo.
Stromal cells, including synovial fibroblasts, maintain T 
cells in a resting G0/G1 state and extend their survival.
49 53 
Thus, synovial fibroblasts keep T cells in the tissue in a 
non-proliferative state and protect them from under-
going apoptosis. In an inflammatory state, this might have 
profound effects on the persistence of inflammation and 
might actively counteract resolution of inflammation. 
Indeed, in the synovium of RA patients, differentiated T 
cells are protected from apoptotic cell death.54 Together, 
these data point to a modulation of the T cell phenotype 
and function by synovial fibroblasts, rather than general 
immunosuppressive properties. Whether this interac-
tion between stroma and invading T cells is promoting 
or counteracting disease development remains, however, 
elusive up to now.
Various different direct adhesive and signalling inter-
actions have been described between synovial fibroblasts 
and T cells as summarised in figure 2. These interactions 
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Figure 2 Overview of key interactions between T cells 
and synovial fibroblasts. ALCAM, activated leukocyte cell 
adhesion molecule; CD40L, CD40 ligand; ICAM-1, 
intercellular adhesion molecule 1; LFA, lymphocyte function-
associated antigen; MHC II, major histocompatibility complex 
II; TNFR1/2, tumour necrosis factor receptor 1/2; VCAM-1, 
vascular cell adhesion protein 1; VLA-4, very late antigen-4.
first promote infiltration and retention of T cells in the 
synovium, for example, very late antigen-4 (VLA-4) and 
vascular cell adhesion protein 1 (VCAM-1) interactions, 
and second activate intracellular signalling pathways 
in both T cells and synovial fibroblasts. The connec-
tion between lymphocyte function-associated antigen 
1 (LFA-1/CD11a) on T cells and intercellular adhe-
sion molecule 1 (ICAM-1/CD54) on synovial fibroblasts 
is of particular interest because of its ability to enhance 
antigen presentation and T cell activation.55 LFA-1/
ICAM-1 binding lowers the threshold for presented 
antigens to induce T cell activation, thereby allowing T 
cell activation by antigens that without this co-stimula-
tion would not elicit a T cell response.56 LFA-1 binding 
by ICAM-1 also amplifies signalling pathways activated 
by T cell receptor binding.56 Interestingly, presentation 
of superantigens in conjunction with ICAM-1 strongly 
inhibits the production of IL-10 by T cells and thus coun-
teracts self-limitation of the immune response.57 Whether 
this ICAM-1-dependent modulation of the T cell cytokine 
profile occurs in RA synovium is, however, not known. 
Similar to ICAM-1/LFA-1, binding of LFA-3 to CD2 and 
of activated leukocyte cell adhesion molecule (ALCAM/
CD166) to CD6 optimises antigen-induced T cell 
responses.58 59
Also, synovial fibroblast functions are modulated by 
T cells, and synovial fibroblasts produce higher levels 
of cytokines such as IL-6 and IL-8 in co-culture with T 
cells.51 52 60 61 Blockade of TNF could inhibit this response 
of synovial fibroblasts, even though no soluble TNF 
was found in the co-cultures.61 The authors therefore 
concluded that membrane-bound TNF on T cells must 
be responsible for this effect.
In summary, there is clear evidence that synovial fibro-
blasts can present antigens to T cells with concurrent 
activation of an immune response and that synovial fibro-
blasts themselves are activated by this cell-cell contact. 
The effect on the phenotype and function of such cell-cell 
contacts on T cells is, however, not clarified in detail, and 
studies are complicated by the complexity of the in vivo 
situation in the RA synovium, which is hard to mimic in 
an artificial in vitro environment.
The role of Synovial fibroblaSTS in The formaTion of 
eCTopiC lymphoid STruCTureS and b Cell Survival
Based on the histology of the synovium, patients with RA 
can be grouped into three subtypes. The fibroid patho-
type is characterised by little infiltration of immune 
cells; in the myeloid pathotype, immune cells invade 
diffusely and monocytes/macrophages are the predom-
inant immune cell type, and in the lymphoid pathotype, 
ectopic lymphoid structures (ELS) that are formed by B 
and T cell aggregates are found.62 63 Whether and how 
ELS contribute to disease pathogenesis has not been clar-
ified in detail, but affinity maturation of B cells in ELS 
and local production of auto-antibodies in ELS could 
be shown in RA synovium.64 65 Based on their cytokine 
expression profile, synovial fibroblasts are believed to 
promote ELS formation and function. Synovial fibro-
blasts of patients with RA and psoriatic arthritis were 
shown to express higher levels of CCL19 and CCL21 than 
synovial fibroblasts from patients with OA.66 Both factors 
are being considered important for the development and 
maintenance of ELS (for review, see Bombardieri et al67). 
Similarly, receptor activator of NF-κB ligand (RANKL)68 
and IL-769 are expressed at higher levels by synovial 
fibroblasts from RA patients compared with OA and are 
crucial factors in ELS development. Synovial fibroblasts 
furthermore promote retention and survival of plasma 
cells that matured in ELS or infiltrated through the circu-
lation in the synovium by the production of CXCL12, 
IL-6, BAFF and APRIL.40 70 71 It is, however, still unclear 
to which extent synovial fibroblasts are actually involved 
in the appearance of ELS and why they only develop in a 
subgroup of RA patients.
inTeraCTionS of Synovial fibroblaSTS wiTh monoCyTeS 
and maCrophageS
There is an intimate relationship between synovial fibro-
blasts and tissue resident synovial macrophages (type A 
synoviocytes) in the synovial tissue. The origin of these 
tissue resident macrophages in the synovium is not known 
to date. Apart from the long-lived, self-renewing tissue 
macrophages, monocytes are recruited from the circu-
lation and mature into monocyte-derived macrophages 
(MDM), in particular during inflammation.72 MDM 
show remarkable plasticity, and in K/BxN serum trans-
fer-induced arthritis in mice, they were shown to switch 
from a proinflammatory phenotype promoting arthritis 
to an anti-inflammatory phenotype necessary to resolve 
arthritis at a later stage of disease.73 The real extent of 
variability of MDM in inflamed synovium can probably 
only be estimated by applying singe cell based technolo-
gies in the future.
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Surprisingly, little data are available addressing the 
role of synovial fibroblasts in macrophage differenti-
ation and phenotypes, even though in other organs, it 
has been shown that the local stroma is crucial for the 
formation of tissue-specialised phenotypes of macro-
phages.74 Synovial fibroblasts can support the survival 
of monocytes in two-dimensional and three-dimen-
sional co-cultures.75 76 Co-culture experiments with syno-
vial fibroblasts and MDM showed that synovial fibroblasts 
suppressed the TNF-induced IFN response of MDM.77 
This effect was found to be based on yet unidentified, 
soluble factors produced by synovial fibroblasts after 
stimulation with TNF. Strikingly, co-culture of synovial 
fibroblasts regulated almost one-third of TNF-induced 
genes in MDM, and there was substantial overlap of syno-
vial fibroblast-regulated genes with genes that were found 
to be specific for synovial macrophages isolated from RA 
patients.77 These data strongly support a role of synovial 
fibroblasts in modulating the phenotype of macrophages 
in the RA synovium, and more studies focusing on this 
issue would be of high interest.
how do Synovial fibroblaSTS invade CarTilage
One of the first described and most characteristic 
features of RA synovial fibroblasts is their capability of 
invading and destroying cartilage. There is evidence 
from mouse models that cartilage structure has to be 
impaired before synovial fibroblasts can attach to carti-
lage. In TNF transgenic (hTNFtg) mice, loss of cartilage 
proteoglycan is a prerequisite for the attachment of and 
thus cartilage damage by synovial fibroblasts.78 Further-
more, collagenase or IL-1 injection into mouse joints 
attracts intravenously injected human RA synovial fibro-
blasts to the joint and promotes attachment and degra-
dation.79 80 These data support the interesting hypothesis 
that synovial fibroblasts that leave the inflamed synovium 
can migrate through the body and spread RA to addi-
tional joints. Which factors are responsible for this attrac-
tion and whether the same mechanisms are operative in 
human RA joints are, however, not known to date.
Integrins and syndecans are adhesion molecules that 
have been implicated in the attachment of synovial fibro-
blasts to cartilage and ECM proteins. In hTNFtg mice, 
attachment of synovial fibroblasts to cartilage was substan-
tially diminished when α2β1 integrin or syndecan 4 expres-
sion was knocked out.78 81 The functions of syndecan 4 are, 
however, manifold, and apart from promoting binding 
to ECM proteins, it binds a variety of growth factors (eg, 
basic fibroblast growth factor) induces cytoskeletal rear-
rangement and activates intracellular signalling path-
ways (for review, see Afratis et al82). Therefore, also other 
properties than ECM binding could be responsible for 
the positive effect of syndecan 4 knockout in the hTNFtg 
arthritis model. In RA synovium, the expression of the 
integrin subunits α5, αv and β1 was specifically increased 
at the site of synovial invasion into cartilage.83 Cultured 
RA synovial fibroblasts adhered significantly more to 
collagen type IV, fibronectin, laminin and tenascin than 
normal synovial fibroblasts and expressed increased levels 
of α5β1 integrins.84 Interestingly, syndecan 4 functions as 
co-receptor of α5β1 integrins in the formation of focal 
adhesions and cell migration as shown in a melanoma 
cell line.85 They also might cooperate in the RA synovium 
to promote cartilage destruction.
α5β1 integrins bind to fibronectin, and levels of 
fibronectin are increased in RA synovium and synovial 
fluids.86 Shiozawa et al found fibronectin at the surface 
of RA, but not OA or healthy cartilage, and staining 
increased inversely to proteoglycan content.87 It was 
suggested that cartilage impairment in RA exposes carti-
lage fibronectin or stimulates fibronectin deposition, 
which might promote binding by synovial fibroblasts.88 
However, additional factors are necessary to promote 
attachment of synovial fibroblasts to cartilage because 
the content of fibronectin is also greatly increased in OA 
cartilage,89 but cartilage damage in OA patients does not 
lead to attachment and invasion of synovial fibroblasts.
Synovial fibroblasts damage cartilage by the produc-
tion of MMPs, a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTs) and cathepsins. 
In particular, MMP1, 3, 9, 13, 14 and 15; ADAMTS4 
and 5; and cathepsins B, L and K are highly expressed 
by synovial fibroblasts in RA joints (for detailed review, 
see Rengel et al90). The production of these protein-
ases is induced by the proinflammatory environment, 
for example, TNF and IL-1 in the inflamed joint. Also, 
epigenetic changes have been found that maintain the 
expression of MMPs at a high level in RA synovial fibro-
blasts.91 Even though many attempts have been made 
to influence cartilage destruction by pharmacological 
targeting of MMPs, none of the trials up to now was 
successful, partly because of lack of effect and partly 
because of serious side effects. An overview of factors that 
are implicated in the attachment of RA synovial fibro-
blasts to cartilage and cartilage destruction is given in 
figure 3.
inTeraCTion of Synovial fibroblaSTS wiTh endoThelial 
CellS and oSTeoClaSTS
Blood vessel growth is increased in RA synovium, and 
synovial fibroblasts have been shown to produce a variety 
of factors that promote angiogenesis such as vascular 
endothelial growth factor and CXCL12 (for detailed 
review, see Elshabrawy et al92). Nevertheless, oxygen 
concentrations are strongly reduced in RA synovium.93 
This hypoxic environment has severe consequences for 
the function of synovial fibroblasts by promoting muta-
tions of mitochondrial DNA leading to mitochondrial 
dysfunction, changes in metabolic activity and increased 
migratory and invasive properties.94 In addition, hypoxia 
was recently shown to induce the release of extracel-
lular RNA from synovial fibroblasts, which might influ-
ence the attachment of synovial fibroblasts to cartilage 
and subsequent invasion.95 The increase in the amount 
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Figure 3 Attachment of rheumatoid arthritis (RA) synovial 
fibroblasts to cartilage and cartilage destruction. Impairment 
of cartilage structure and loss of proteoglycan were 
described as initiating events in the attachment of synovial 
fibroblasts to cartilage. Increased expression of α5β1 and its 
co-receptor syndecan 4 in RA synovial fibroblasts promotes 
binding of fibronectin, which can be deposited or exposed 
in damaged cartilage. High levels of proinflammatory 
factors such as tumour necrosis factor (TNF), interleukin 
(IL) 1 and toll-like receptor (TLR) ligands stimulate synovial 
fibroblasts to produce matrix-degrading molecules such 
as matrix metalloproteinases (MMPs), a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS) 
and cathepsins.
of blood vessels supports the recruitment of leukocytes 
in the inflamed synovium. Interactions between syno-
vial, but not dermal fibroblasts with endothelial cells, 
were shown to increase the adhesion and migration of 
lymphocytes and neutrophils.96 97 Interestingly, under 
inflammatory conditions (in vitro stimulation with TNF 
and IFNγ), synovial fibroblasts from non-inflamed and 
resolving arthritis inhibited lymphocyte recruitment, 
while RA synovial fibroblasts did not.98 This was also true 
for synovial fibroblasts isolated from RA patients before 
they fulfilled RA classification criteria, showing that this 
change in fibroblast behaviour occurs at a very early stage 
of disease.98
Bone erosion is another classical feature of RA that is 
influenced by synovial fibroblasts. Production of proin-
flammatory cytokines and RANKL by synovial fibroblasts 
directly promotes osteoclastogenesis (for detailed review, 
see Wehmeyer et al99). Myostatin, a member of the trans-
forming growth factor-β family, was shown to be strongly 
expressed by synovial fibroblasts in RA synovium and to 
enhance RANKL-mediated osteoclastogenesis.100
epigeneTiC imprinTing of Synovial fibroblaSTS
Epigenetic mechanisms can induce stable changes in 
gene expression without altering the DNA sequence. 
They are essential during development and define 
tissue- and cell-specific gene expression. Later in life, the 
epigenetic landscape can still be modulated by environ-
mental influences, which is a possibility for cells to adapt 
to an altered environment. However, shifts in the epige-
netic landscape can also lead to the stable imprinting of 
pathological changes in gene expression. In RA synovial 
fibroblasts, a stably activated, aggressive phenotype has 
been described more than 20 years ago.101 102 Since then, 
a variety of epigenetic modifications, mostly DNA meth-
ylation, but also histone modifications and changes in 
non-coding RNA have been described to be altered in RA 
synovial fibroblasts compared with OA or healthy syno-
vial fibroblasts and have been made responsible for the 
development of this disease-specific phenotype. The find-
ings of the various studies analysing epigenetic changes 
in RA synovial fibroblasts will only briefly discussed here, 
since several review articles were recently published that 
focused in more detail on this particular topic.103–105
Studies analysing changes in DNA methylation in 
RA synovial fibroblasts could show that specific genes 
and pathways connected to the pathogenesis of RA are 
affected by these changes, which suggests that these alter-
ations do not occur arbitrarily but are introduced by 
directed processes.106–108 Which processes might cause 
the changes in DNA methylation in RA synovial fibro-
blasts is largely unknown. Besides hypomethylation and 
hypermethylation connected to coding regions and gene 
expression in RA, a globally hypomethylated state, which 
presumably stems from a loss of DNA methylation in 
sequences harbouring retrotransposons, were found.109 
Global hypomethylation often occurs in high prolifer-
ative cells and is connected to an increased recycling 
of polyamines, competing with the DNA methylating 
enzyme for the same methyl donor.110 How the subse-
quent expression of retrotransposable elements such as 
long interspersed element-1 (LINE-1) contributes to the 
aggressive phenotype of synovial fibroblasts is, however, 
not known.
The study of histone modifications is technically much 
more challenging than the analysis of DNA methylation. 
Accordingly, few studies analysing histone modifications 
were conducted in synovial fibroblasts. As yet, mainly 
histone acetylation and its modifying enzymes have 
been studied.111 Histone deacetylases (HDACs) have 
emerged as therapeutic targets in RA with HDAC inhib-
itors showing promising anti-inflammatory properties in 
a variety of cell types and animal models. Probably, this 
effect is based on modulation of histone acetylation as 
well as of changes in acetylation of non-histone proteins, 
such as transcription factors.
Apart from DNA methylation and histone modifi-
cations, non-coding RNAs, in particular microRNAs, 
are altered in RA synovial fibroblasts.112 113 MicroRNAs 
are small non-coding RNA molecules that can inhibit 
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translation of proteins by binding of complementary 
messenger RNA (mRNA). The identification of the targets 
and pathways that are altered by differentially expressed 
microRNAs in RA synovial fibroblasts is, however, chal-
lenging, since one microRNA can bind several hundred 
different target mRNAs and one mRNA can be targeted 
by several microRNAs.
In summary, major advances have been made in the 
identification of epigenetic modifications that are altered 
in RA synovial fibroblasts. Epigenetic research now needs 
to go a step further and decipher how and at which stage 
of the disease these changes are introduced and what 
functional consequences they really have.
SubTypeS of Synovial fibroblaSTS
In earlier days, it was assumed that all fibroblasts 
throughout the body are similar and their function is 
limited to providing the extracellular framework for the 
more specialised tissue and immune cells. Nowadays, 
it is well known that fibroblasts from different anatom-
ical sites are distinct and fulfil specialised functions; for 
example, synovial fibroblasts interact differently with 
local cells and immune cells than dermal fibroblasts and 
produce different molecules on stimulation.2 96
Newer data support the notion that the population of 
synovial fibroblasts is also heterogeneous and that several 
distinct subtypes of synovial fibroblasts exist. Synovial 
fibroblasts isolated from different joints show distinct 
phenotypes.114 115 They differ in their gene expression 
patterns, epigenetic marks and functions, which could 
explain why some joints are more susceptible to develop 
certain kinds of arthritis than others are.114 In particular, 
Hox genes that are expressed in a strictly controlled, 
time- and location-dependent manner during limb devel-
opment are differentially expressed in synovial fibroblasts 
from different joints and maintain the same pattern of 
expression that was established during embryogenesis.114 
Not a lot is known about the function of Hox genes in 
adult cells, but their continuous expression in a joint-spe-
cific manner together with some preliminary experi-
ments114 suggests that they have a role in joint physiology 
and probably also in joint pathology.
Also within the synovium, heterogeneous populations 
of synovial fibroblasts are found. Synovial fibroblasts in 
the lining layer express the adhesion molecule VCAM-1, 
phosphodiesterase, cadherin-11 and gp38 (podo-
planin), whereas synovial fibroblasts in the sublining 
layer express CD90 and CD248.116 117 This separation is 
even more pronounced in the hyperplastic lining layer 
of RA synovium and might play a role in the adhesive 
properties of RA synovium. Cadherin-11-deficient 
mice lack the typical organisation of the synovium into 
lining and sublining layer and develop ameliorated 
arthritis compared with wild-type mice as shown in the 
K/BxN serum transfer model.116 However, also CD248 
knockout mice develop less severe collagen antibody-in-
duced arthritis than wild-type mice, with less synovial 
hyperplasia and cartilage destruction, suggesting that 
also molecules expressed primarily in the sublining layer 
can influence synovial hyperplasia and invasion.118 These 
studies underline the importance of synovial fibroblasts 
in arthritis development, but further studies are needed 
to fully characterise differences in synovial fibroblasts 
within the synovium and their specific roles in arthritis 
development.
ConCluSion and ouTlook
There is an increasing interest of the research commu-
nity in analysing synovial fibroblasts and their role in 
arthritis development. From the many in vitro and in vivo 
studies, we learnt that synovial fibroblasts are critical in 
promoting destructive arthritis and produce a variety of 
factors that drive joint inflammation and joint destruc-
tion. They are innate immune cells that can sense path-
ogens and danger molecules in their environment and 
respond by the production of chemokines and cytokines. 
Furthermore, they are able to present antigen and elicit 
an adaptive immune response. In RA, they exhibit a stably 
altered phenotype and attach to and destroy cartilage. At 
the same time, they show profound changes in their epig-
enome, which might be responsible for this alteration in 
phenotype.
Despite this wealth of knowledge gained in the last 
years, many questions are still open that need to be 
answered to fully understand the role of synovial fibro-
blasts in the development of destructive arthritis. It is not 
clear at which stage of disease and how synovial fibro-
blasts become activated and phenotypically altered in RA. 
Furthermore, studies that connect epigenetic changes 
with functional changes in synovial fibroblasts are still 
rare. Cell adhesion pathways are predicted to be altered 
by changes in DNA methylation in RA synovial fibro-
blasts,107 but it is not really known which adhesion mole-
cules are crucial for the attachment of synovial fibroblasts 
to cartilage, a process that is typical for RA synovium and 
a key step in disease development. Finally, the question 
why this process only happens in some joints, but not in 
others, remains unresolved. Further characterisation of 
the different subtypes of synovial fibroblasts might clarify 
the question which type of synovial fibroblasts drive 
destruction at which anatomical site.
The fascinating technical advances of recent years, 
such as single cell based transcriptome and proteome 
analysis, gene editing by the CRISPR/Cas9 system and 
high-resolution imaging techniques, will certainly drive 
scientific insights in the years to come. With the help 
of these techniques, it will be possible to get a clear 
picture of the biology of synovial fibroblasts in health 
and disease and their interactions with their neigh-
bouring cells and tissues. Interdisciplinary integration of 
data and knowledge gained from genetics, immune and 
stroma cell analysis will be key to develop a comprehen-
sive model of disease pathogenesis and preventive treat-
ment strategies.
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